MERCK RECEIVES POSITIVE EU CHMP OPINION TO EXPAND MARKETING AUTHORIZATION FOR ENFLONSIA® (CLESROVIMAB) TO INCLUDE CHILDREN UP TO 24 MONTHS OF AGE WHO REMAIN VULNERABLE TO SEVERE RSV DISEASE THROUGH THEIR SECOND RSV SEASON

Reuters · 22h ago

Please log in to view news